Bayer cautions pharma sales dip this year despite major upcoming launches
Bayer said Wednesday its pharmaceuticals unit will likely see a decline in sales in 2025, as the company reported another set of lackluster earnings amid its best efforts at a multiyear turnaround. The...
View ArticleJazz to buy Chimerix for $935M to get brain tumor drug five months ahead of...
Jazz Pharmaceuticals will buy North Carolina biotech Chimerix for $935 million in cash, the companies said Wednesday morning. Through the deal, Jazz gets access to a potential first-ever treatment for...
View ArticleBhattacharya hearing updates: Trump NIH nominee faces Senate
Stanford researcher Jay Bhattacharya appears headed for a relatively easy Senate confirmation, following a two-hour hearing where he was pressed on several controversial topics but largely appeared to...
View ArticleFDA puts BioNTech’s malaria vaccine on clinical hold
BioNTech has paused an early-stage study of its experimental malaria vaccine after the FDA handed it a clinical hold, the biotech disclosed Tuesday in a securities filing. The company did not provide a...
View ArticleBristol Myers' MyoKardia unit ends work with Fulcrum; ALX discloses layoffs
Plus, news about Amgen, Tenax Therapeutics and Celon Pharma: Fulcrum Therapeutics loses a partner: Bristol Myers Squibb’s MyoKardia unit told Fulcrum last week that it is terminating a
View ArticleNovo Nordisk slashes Wegovy price for patients without insurance
Novo Nordisk cut the price of its weight loss blockbuster Wegovy by nearly two-thirds for certain patients paying outside of insurance, following a similar move by Eli Lilly. Novo’s new program...
View ArticleTrump administration reverses course on FDA drug quality lab closure
Two days after announcing plans to shut down an FDA lab devoted to ensuring the US drug supply remains safe and potent, the Trump administration has changed plans and will leave the lab open, ...
View ArticleBavarian Nordic CEO says reshoring manufacturing to the US can take years
While reshoring pharma production to the US is not impossible, government officials need to be aware that it could take five to 10 years to complete the process, Bavarian Nordic CEO Paul Chaplin...
View ArticleNovo Nordisk will join lawsuit over end of semaglutide shortage
Novo Nordisk got the green light to join a lawsuit by compounders against the FDA after the agency deemed that the Danish pharma's blockbuster weight loss drug was no longer in shortage. Judge Mark...
View ArticleJudge grants new nationwide block on NIH payment cuts
A federal judge on Wednesday blocked the NIH from issuing a cap on indirect cost payments for grantees after finding that the challengers are likely to show the cuts conflict with the law. Judge Angel ...
View ArticleITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera
ITM Isotope Technologies Munich’s radiopharma candidate reduced neuroendocrine tumor patients’ risk of progression or death by a third compared with standard therapy, according to pivotal data...
View ArticleNovo Nordisk looks into starting GLP-1 drug trials for addiction
Novo Nordisk is considering investigating its GLP-1 therapies in the treatment of addictions, mirroring similar comments made by its major incretin rival Eli Lilly. Novo is already studying its GLP-1...
View ArticleNo news is good news? Merck KGaA quiet on potential SpringWorks takeover
Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its potential buyout of SpringWorks Therapeutics. But the German pharma was...
View ArticleMakary hearing updates: Trump FDA nominee faces Senate
Johns Hopkins surgeon Marty Makary, President Donald Trump's pick to lead the FDA, emerged from his Senate confirmation hearing relatively unscathed. During the less than two-hour hearing, Makary vowed...
View ArticleDenali stops some work on ALS drug after analysis showed no impact on key...
Denali Therapeutics’ ALS program showed no effect on an important neurodegeneration biomarker that could have been used for FDA approval after a failed topline readout earlier this year. The company is...
View ArticleMerck KGaA says earlier moves to localize manufacturing help ease Trump...
Merck KGaA flagged that it might get hit by President Donald Trump’s tariffs against China, but CEO Belén Garijo said this is likely to be “manageable” due to its earlier execution of regionalizing its...
View ArticleCorrected: Merck KGaA’s mixed Phase 2 lupus results; Zymeworks pauses work on...
Plus, news about Tris Pharma and ARS Pharmaceuticals: Merck KGaA’s lupus drug yields mixed data in mid-stage trial: The drugmaker’s TLR7/8 inhibitor, called enpatoran, missed one of two Phase 2 primary...
View ArticleLuxa's stem cell therapy for dry AMD shows early promise
Luxa Biotechnology said Thursday that its stem cell therapy helped improve vision in a handful of people with a common form of an age-related eye condition. In its lowest dose cohort, the Phase 1/2a...
View ArticleNovo Nordisk’s rare disease ‘company within a company’ has an open goal in...
Novo Nordisk is known for making therapies for some of the world’s most prevalent conditions, but it's also working on candidates for some of the least common. Though the company’s rare disease unit is...
View Article